Back to Search Start Over

COVID-19 Drug Development.

Authors :
Kim S
Source :
Journal of microbiology and biotechnology [J Microbiol Biotechnol] 2022 Jan 28; Vol. 32 (1), pp. 1-5.
Publication Year :
2022

Abstract

Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges.

Details

Language :
English
ISSN :
1738-8872
Volume :
32
Issue :
1
Database :
MEDLINE
Journal :
Journal of microbiology and biotechnology
Publication Type :
Academic Journal
Accession number :
34866128
Full Text :
https://doi.org/10.4014/jmb.2110.10029